Sucralfate (Monograph)

Brand name: Carafate
Drug class: Protectants
- Antiulcer Agents
ATC class: A02BX02
VA class: GA302
CAS number: 54182-58-0

Introduction

Antiulcer agent; anionic sulfated disaccharide.^a ^b ^c

Uses for Sucralfate

Duodenal Ulcer

Short-term (up to 8 weeks) treatment of active duodenal ulcer.^a ^b ^c

Maintenance of healing and reduction in recurrence of duodenal ulcer.^a ^c

Conventional antiulcer therapy, including sucralfate therapy, is associated with a high rate of ulcer recurrence (e.g., 60–100% per year) in patients with initial or recurrent duodenal ulcer and documented Helicobacter pylori infection.¹⁰⁰ ¹³² ¹³⁶ ¹⁴⁰ ¹⁴⁴ ¹⁴⁶ ¹⁵⁴ All such patients should receive anti-infective therapy for treatment of the infection;¹²⁸ ¹³² ¹⁴⁴ ¹⁴⁵ ¹⁴⁶ choice of a particular regimen should be based on current data on optimal therapy.¹²⁸ ¹³² ¹⁴⁰ ¹⁴⁵ ¹⁶⁵ ¹⁶⁶

Efficacy of short-term sucralfate similar to that of cimetidine in adults with duodenal ulcer.^a

Gastric Ulcer

Short-term treatment of gastric ulcer^{† [off-label]}.^a

Conventional antiulcer therapy, including sucralfate therapy, is associated with a high rate of ulcer recurrence (e.g., 60–100% per year) in patients with initial or recurrent gastric ulcer and documented H. pylori infection.¹⁰⁰ ¹³² ¹³⁶ ¹⁴⁰ ¹⁴⁴ ¹⁴⁶ ¹⁵⁴ All such patients should receive anti-infective therapy for treatment of the infection;¹²⁸ ¹³² ¹⁴⁴ ¹⁴⁵ ¹⁴⁶ choice of a particular regimen should be based on current data on optimal therapy.¹²⁸ ¹³² ¹⁴⁰ ¹⁴⁵ ¹⁶⁵ ¹⁶⁶

Chemotherapy-induced Mucositis

Has been used as an oral suspension^{† [off-label]} for prevention and treatment of chemotherapy-induced mucositis^{† [off-label]}.¹⁰⁰ ¹⁰¹ ¹⁰² ¹⁰³ ¹⁰⁴ ¹⁰⁸ Results have been conflicting;¹⁰¹ additional study necessary.¹⁰⁰ ¹⁰⁴ ¹⁰⁶ ¹⁰⁷

Sucralfate Dosage and Administration

General

Equivalence of sucralfate suspension and tablets not demonstrated.^b

Administration

Oral Administration

Administer orally on an empty stomach, 1 hour before each meal and at bedtime.^a ^b ^c

Agitate suspension well prior to administration of each dose.^b

Antacids may be given as necessary for pain relief but should not be taken within 30 minutes before or after sucralfate.^a ^b ^c (See Specific Drugs under Interactions.)

NG Tube

Bezoars may form with concomitant use of sucralfate and enteral tube feedings.^a ^b ^c (See Bezoars under Cautions.)

Dosage

Adults

Duodenal Ulcer

Treatment

Oral

1 g 4 times daily for 4–8 weeks.^a ^b ^c

Although healing may occur during first 2 weeks of therapy, continue treatment for full 4–8 weeks unless healing is confirmed by radiographic or endoscopic examination.^a ^b ^c

Maintenance of Healing

Oral

1 g twice daily.^a ^c

Gastric Ulcer† [off-label]

Oral

1 g 4 times daily.^a

Special Populations

Hepatic Impairment

No specific dosage recommendations at this time.^a ^b ^c

Renal Impairment

No specific dosage recommendations at this time.^a ^b ^c (See Renal Impairment under Cautions.)

Geriatric Patients

Select dosage with caution because of age-related decreases in hepatic, renal, and/or cardiac function and concomitant disease and drug therapy.^b

Cautions for Sucralfate

Contraindications

Manufacturer states that there are no known contraindications to use of sucralfate.^b ^c

Warnings/Precautions

General Precautions

Although sucralfate may result in complete ulcer healing, it does not alter the post-healing frequency or severity of duodenal ulceration; duodenal ulcer is a chronic, recurrent disease.^a ^b ^c

Administration Precautions

Do not administer IV; may cause fatal complications, including pulmonary and cerebral emboli.^a ^b ^c

Bezoars

Formation of bezoars reported, primarily in patients with underlying predisposing medical conditions (e.g., delayed gastric emptying) or those receiving concomitant enteral tube feedings.^a ^b ^c

Specific Populations

Pregnancy

Category B.^b ^c

Lactation

Not known whether sucralfate is distributed into milk.^a ^b ^c Caution if used in nursing women.^a ^b ^c

Pediatric Use

Safety and efficacy not established.^a ^b ^c

Geriatric Use

Insufficient experience in patients ≥65 years of age to determine whether geriatric patients respond differently than younger adults; select dosage with caution.^b

Substantially eliminated by kidneys; assess renal function periodically since geriatric patients are more likely to have decreased renal function.^b

Renal Impairment

Use with caution in patients with chronic renal failure or those undergoing dialysis; possible impaired excretion of absorbed aluminum.¹⁰⁹ ^a ^b ^c

Possible aluminum accumulation and toxicity (e.g., aluminum osteodystrophy, osteomalacia, encephalopathy) in patients with renal impairment.^a ^b ^c

Common Adverse Effects

Constipation.^a ^b ^c

Drug Interactions

Effects on GI Absorption of Drugs

May bind to a number of drugs in the GI tract, reducing extent of absorption.^a ^b ^c Instruct patients to administer other drugs at least 2 hours before sucralfate and monitor patients appropriately if alteration in bioavailability of the other drug(s) is critical.^a ^b ^c

Specific Drugs

Drug	Interaction	Comments
Antacids	Aluminum-containing antacids: Concomitant use may increase total body burden of aluminum, possibly resulting in aluminum toxicity (see Renal Impairment under Cautions)^b ^c	Aluminum-containing antacids: Use caution in patients with chronic renal failure or those undergoing dialysis^b ^c All antacids: Take antacids at least 30 minutes before or after sucralfate^a ^b ^c
Cimetidine	Possible decreased absorption of cimetidine^a ^b ^c	Take cimetidine 2 hours before sucralfate^b ^c
Digoxin	Possible decreased absorption of digoxin^a ^b ^c	Take digoxin 2 hours before sucralfate^b ^c
Fluoroquinolone antibiotics (e.g., ciprofloxacin, norfloxacin, ofloxacin)	Possible decreased absorption of fluoroquinolone¹¹⁰ ¹¹¹ ¹¹² ¹¹³ ¹¹⁴	Take fluoroquinolones 2 hours before sucralfate¹¹¹ ¹¹³ ¹¹⁴
Ketoconazole	Possible decreased absorption of ketoconazole^a ^b ^c	Take ketoconazole 2 hours before sucralfate^b ^c
Levothyroxine	Possible decreased absorption of levothyroxine^b ^c	Take levothyroxine 2 hours before sucralfate^b ^c
Phenytoin	Possible decreased absorption of phenytoin^a ^b ^c	Take phenytoin 2 hours before sucralfate^b ^c
Quinidine	Possible decreased absorption of quinidine^b ^c	Take quinidine 2 hours before sucralfate^b ^c
Ranitidine	Possible decreased absorption of ranitidine^a ^b ^c	Take ranitidine 2 hours before sucralfate^b ^c
Tetracycline	Possible decreased absorption of tetracycline^a ^b ^c	Take tetracycline 2 hours before sucralfate^b ^c
Theophylline	Possible decreased absorption of theophylline^a ^b ^c	Take theophylline 2 hours before sucralfate^b ^c
Warfarin	Possible decreased absorption of warfarin;^a ^b ^c may result in subtherapeutic PT^b	Take warfarin 2 hours before sucralfate^b ^c

Sucralfate Pharmacokinetics

Absorption

Bioavailability

Minimally absorbed following oral administration.^a ^b ^c

Duration

Binding to ulcer site persists for up to 6 hours.^a

Distribution

Extent

Minimally distributed into tissues.^a

Not known whether sucralfate crosses the placenta or is distributed into milk.^a ^b ^c

Elimination

Metabolism

Reacts with hydrochloric acid in the stomach to form sucrose sulfate, which is not metabolized.^a

Elimination Route

Excreted principally in feces (>90%) and urine (3–5%) as sucrose sulfate within 48 hours.^a

Stability

Storage

Oral

Tablets

Tight containers at room temperature.^a

Suspension

20–25°C;^b do not freeze.^a ^b

Actions

Anionic sulfated disaccharide; pepsin inhibitor.^a ^b ^c
Exact mechanism(s) of action unclear; therapeutic effects result from local (i.e., at the ulcer site) rather than systemic activity.^a ^b ^c
Does not affect gastric acid output or concentration; ^a does not neutralize acidity of gastric contents.^a
Reacts with hydrochloric acid in the stomach; forms highly condensed, viscous, adhesive, paste-like substance that buffers acid (14–16 mEq of in vitro acid-neutralizing capacity per 1-g dose).^a ^b ^c
Binds to surface of gastric and duodenal ulcers with greater affinity for ulcer site than normal GI mucosa; also binds to acute gastric erosions produced by alcohol or other drugs (e.g., aspirin).^a
Binds electrostatically to positively charged protein molecules in damaged mucosa of the GI tract, forming insoluble, stable complexes which form an adherent, protective barrier at the ulcer site.^a ^b ^c
Allows ulcer to heal by protecting ulcer site from ulcerogenic properties of pepsin, acid, and bile; prevents back diffusion of hydrogen ions and adsorbs pepsin and bile acids.^a ^b ^c
May decrease rate of gastric emptying.^a

Advice to Patients

Importance of taking sucralfate on an empty stomach.^a ^b ^c
Importance of shaking suspension well prior to each use.^b
Importance of not taking antacids 30 minutes before or after sucralfate dose.^a ^b ^c
Importance of completing full course of therapy, unless healing is shown on radiographic or endoscopic examination.^a ^b ^c
Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs and dietary or herbal supplements, as well as any concomitant illnesses (e.g., renal failure).^a ^b ^c
Importance of women informing their clinician if they are or plan to become pregnant or plan to breast-feed.^a ^b ^c
Importance of informing patients of other important precautionary information. (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Please refer to the ASHP Drug Shortages Resource Center for information on shortages of one or more of these preparations.

* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name

Sucralfate
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Oral	Suspension	500 mg/5 mL	Carafate (with methylparaben)	Axcan
	Tablets	1 g*	Carafate (scored)	Axcan
			Sucralfate Tablets	Eon

† Off-label: Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

100. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993; 12:34-48. https://pubmed.ncbi.nlm.nih.gov/8428432

101. Blaser MJ. Helicobacter pylori: its role in disease. Clin Infect. 1992; 15:386-91.

102. Marshall BJ. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993; 22:183-98. https://pubmed.ncbi.nlm.nih.gov/8449566

103. Bayerdorffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. https://pubmed.ncbi.nlm.nih.gov/8341987

104. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.

105. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol Suppl. 1993; 196:12-6. https://pubmed.ncbi.nlm.nih.gov/8341986

106. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196:34-7. https://pubmed.ncbi.nlm.nih.gov/8341989

107. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. https://pubmed.ncbi.nlm.nih.gov/8341990

108. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. https://pubmed.ncbi.nlm.nih.gov/8450375

109. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6. https://pubmed.ncbi.nlm.nih.gov/1891021

110. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31. https://pubmed.ncbi.nlm.nih.gov/1891020

111. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993; 341:1359-62. https://pubmed.ncbi.nlm.nih.gov/8098787

112. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991; 83:1734-9. https://pubmed.ncbi.nlm.nih.gov/1770552

113. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-5. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1670011/ https://pubmed.ncbi.nlm.nih.gov/2059685

114. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst. 1991; 83:1702-3. https://pubmed.ncbi.nlm.nih.gov/1770545

115. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104. https://pubmed.ncbi.nlm.nih.gov/8449573

116. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med. 1991; 325:1170-1.

117. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol. 1993; 24:569-70.

118. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori. Lancet. 1990; 335:1233-5. https://pubmed.ncbi.nlm.nih.gov/1971318

119. Hunt RH. pH and Hp—gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88:481-3. https://pubmed.ncbi.nlm.nih.gov/8470623

120. Reviewers’ comments (personal observations) on Helicobacter pylori; 1993 Oct 26.

121. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89(Suppl):S116-28.

122. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1375447/ https://pubmed.ncbi.nlm.nih.gov/8406147

123. Anon. Drugs for treatment of peptic ulcers. Med Lett Drugs Ther. 1994; 36:65-7. https://pubmed.ncbi.nlm.nih.gov/7912812

124. Freston JW. Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol Suppl. 1994; 201:49-54. https://pubmed.ncbi.nlm.nih.gov/8047824

125. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol Suppl. 1994; 201:16-23. https://pubmed.ncbi.nlm.nih.gov/8047818

126. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. https://pubmed.ncbi.nlm.nih.gov/8172146

127. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374625/ https://pubmed.ncbi.nlm.nih.gov/8307443

128. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9. https://pubmed.ncbi.nlm.nih.gov/8007082

129. Fennerty MB. Helicobacter pylori. Ann Intern Med. 1994: 154;721-7.

130. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89:39-42. https://pubmed.ncbi.nlm.nih.gov/8273795

131. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. https://pubmed.ncbi.nlm.nih.gov/8741237

132. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. https://pubmed.ncbi.nlm.nih.gov/8594244

133. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Clin Infect Dis. 1992; 15(Suppl 1):S268-73.

134. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992; 87:1716-27. https://pubmed.ncbi.nlm.nih.gov/1449132

135. Glassman MS. Helicobacter pylori infection in children. A clinical overview. Clin Pediatr (Phila). 1992; 31:481-7. https://pubmed.ncbi.nlm.nih.gov/1643767

136. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991; 324:1043-8. https://pubmed.ncbi.nlm.nih.gov/2005942

137. Logan RP, Gummett PA, Misiewicz JJ et al. One week eradication regimen for Helicobacter pylori. Lancet. 1991; 338:1249-52. https://pubmed.ncbi.nlm.nih.gov/1682653

138. Burette A, Glupczynski Y. On: The who’s and when’s of therapy for Helicobacter pylori. 1991; 86:924-5. Letter.

139. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut. 1993; 34:466-9. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1374304/ https://pubmed.ncbi.nlm.nih.gov/8491391

140. Reviewers’ comments (personal observations) on the Aminopenicillins General Statement 8:12.16.

141. Bell GD, Powell KU, Burridge SM et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med. 1993; 86:743-50. https://pubmed.ncbi.nlm.nih.gov/8265776

142. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994; 89:1785-8. https://pubmed.ncbi.nlm.nih.gov/7942667

143. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994; 89:1793-6. https://pubmed.ncbi.nlm.nih.gov/7942669

144. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91. https://pubmed.ncbi.nlm.nih.gov/7666920

145. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Saf. 1996; 15:30-52. https://pubmed.ncbi.nlm.nih.gov/8862962

146. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs. 1995; 6:984-90.

147. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1:6-19. https://pubmed.ncbi.nlm.nih.gov/9398908

148. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1:138-44. https://pubmed.ncbi.nlm.nih.gov/9398894

149. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 1996; 38:25-34. https://pubmed.ncbi.nlm.nih.gov/8598824

150. Graham DY, Go MF. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:293-4. https://pubmed.ncbi.nlm.nih.gov/8399892

151. Murray DM, DuPont HL. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:294-5.

152. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust. 1990; 153:145-9. https://pubmed.ncbi.nlm.nih.gov/1974027

153. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of Helicobacter pylori. Lancet. 1991; 337:1614. https://pubmed.ncbi.nlm.nih.gov/1675746

154. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Clin Infect Dis. 1990; 12(Suppl 1):S87-93.

155. Graham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann Intern Med. 1991; 115:266-9. https://pubmed.ncbi.nlm.nih.gov/1854110

156. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992; 116:705-8. https://pubmed.ncbi.nlm.nih.gov/1558340

157. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993; 88:505-9. https://pubmed.ncbi.nlm.nih.gov/8470629

158. Logan RP, Gummett PA, Hegarty BT et al. Clarithromycin and omeprazole for Helicobacter pylori. Lancet. 1992; 25:340:239.

159. Hentschel E, Brandstatter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328:308-12. https://pubmed.ncbi.nlm.nih.gov/8419816

160. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993; 328:349-50. https://pubmed.ncbi.nlm.nih.gov/8419823

161. Hosking SW, Ling TK, Yung MY et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ. 1992; 305:502-4. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1882868/ https://pubmed.ncbi.nlm.nih.gov/1392995

162. Bell GD, Powell K, Burridge SM et al. Experience with ’triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992; 6:427-35. https://pubmed.ncbi.nlm.nih.gov/1420735

163. Borody T, Andrews P, Mancuso N et al. Helicobacter pylori reinfection 4 years post-eradication. Lancet. 1992; 339:1295. https://pubmed.ncbi.nlm.nih.gov/1349686

164. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med. 1992; 152:726-32. https://pubmed.ncbi.nlm.nih.gov/1558429

165. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1135. https://pubmed.ncbi.nlm.nih.gov/8827957

166. Soll AH. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1136-7.

167. Langtry HD, Wilde MI. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997; 54:473-500. https://pubmed.ncbi.nlm.nih.gov/9279507

168. TAP Pharmaceuticals, Inc. Prevacid (lansoprazole) delayed-release capsules prescribing information. Deerfield, IL; 1997 Aug.

169. Garnett RG. Lansoprazole: a proton pump inhibitor. Ann Pharmacother. 1996; 30:1425. https://pubmed.ncbi.nlm.nih.gov/8968456

170. Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacotherapy. 1997; 17:308-26. https://pubmed.ncbi.nlm.nih.gov/9085323

171. Hatlebakk JG, Nesje LB, Hausken T et al. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol. 1995; 11:1053-7.

a. AHFS drug information 2007. McEvoy GK, ed. Sucralfate. Bethesda, MD: American Society of Health-System Pharmacists; 2007:2983-5.

b. Axcan Scandipharm Inc. Carafate (sucralfate) suspension prescribing information. Birmingham, AL; 2004 Apr.

c. Axcan Scandipharm Inc. Carafate (sucralfate) tablets prescribing information. Birmingham, AL; 2004 Mar.

d. Konturek SJ, Kwiecien N, Obtulowicz W et al. Double blind controlled study on the effect of sucralfate on gastric prostaglandin formation and microbleeding in normal and aspirin treated man. Gut. 1986; 27:1450-6. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1433967/ https://pubmed.ncbi.nlm.nih.gov/3492413